Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
This study showed that, in aggregate, an injection of mesenchymal stem cells as a therapy for patients with ischemic cardiomyopathy favorably affected their functional capacity, quality of life, and ventricular remodeling.
- Journal: Journal of the American Medical Association
- Year: 2012
- Topic: Heart Failure, Stem Cells
- Read more articles by: Gary Gerstenblith, MD
